About Alder BioPharmaceuticals (NASDAQ:ALDR)
Alder BioPharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine and other serious neurological or inflammatory conditions in the United States, Australia, and Ireland. The company's lead pivotal-stage product candidate, Eptinezumab, a monoclonal antibody inhibiting calcitonin gene-related peptide, which is in Phase III pivotal trials for the prevention of migraine. Its product candidate pipeline also includes ALD1910, a preclinical monoclonal antibody that targets pituitary adenylate cyclase-activating polypeptide-38; and Clazakizumab, that has completed two Phase 2b clinical trials designed to block the pro-inflammatory cytokine IL-6. Alder BioPharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Bothell, Washington.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ALDR
CUSIPN/A
Phone425-205-2900
Debt
Debt-to-Equity RatioN/A
Current Ratio12.30%
Quick Ratio12.30%
Price-To-Earnings
Trailing P/E Ratio-2.93
Forward P/E Ratio-3.31
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.62 million
Price / Sales589.71
Cash FlowN/A
Price / CashN/A
Book Value$4.12 per share
Price / Book3.42
Profitability
EPS (Most Recent Fiscal Year)($4.95)
Net Income$-288,870,000.00
Net MarginsN/A
Return on Equity-103.76%
Return on Assets-93.09%
Miscellaneous
Employees193
Outstanding Shares67,850,000
Alder BioPharmaceuticals (NASDAQ:ALDR) Frequently Asked Questions
What is Alder BioPharmaceuticals' stock symbol?
Alder BioPharmaceuticals trades on the NASDAQ under the ticker symbol "ALDR."
How were Alder BioPharmaceuticals' earnings last quarter?
Alder BioPharmaceuticals (NASDAQ:ALDR) posted its earnings results on Monday, February, 26th. The biopharmaceutical company reported ($0.80) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.03) by $0.23. The biopharmaceutical company had revenue of $0.94 million for the quarter. During the same period in the previous year, the company earned ($0.97) EPS. View Alder BioPharmaceuticals' Earnings History.
What price target have analysts set for ALDR?
12 Wall Street analysts have issued 1 year price objectives for Alder BioPharmaceuticals' stock. Their forecasts range from $11.00 to $51.00. On average, they expect Alder BioPharmaceuticals' stock price to reach $28.1667 in the next twelve months. View Analyst Ratings for Alder BioPharmaceuticals.
What are Wall Street analysts saying about Alder BioPharmaceuticals stock?
Here are some recent quotes from research analysts about Alder BioPharmaceuticals stock:
- 1. Mizuho analysts commented, "We spoke with the company a couple of times late last week and this week after the announcement that CEO Randall Schatzman was stepping down. Our view on eptinezumab having a competitive and differentiated profile in the crowded migraine space has not changed. While the CEO transition brings uncertainties, it may help position the company as a commercial organization sooner. In our view, the best way to unlock the value of eptinezumab is through an acquisition by a larger company with substantial U.S. commercial experience. We recommend buying the shares on weakness." (3/28/2018)
- 2. According to Zacks Investment Research, "Alder Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and seeks to commercialize therapeutic antibodies. It is developing monoclonal antibodies comprising ALD403, for the prevention of migraine; and Clazakizumab, in the treatment of rheumatoid arthritis and psoriatic arthritis. Alder Biopharmaceuticals Inc. is headquartered in Bothell, Washington. " (3/1/2018)
- 3. Needham & Company LLC analysts commented, "Results from the ongoing pivotal Phase 3 PROMISE-1 trial in patients with frequent episodic migraines (FEM) are expected this month. In the context of positive Phase 3 FEM results from all competitor CGRP antibody programs (AMGN, LLY, TEVA), we think PROMISE-1’s primary endpoint will generally be in-line with the competition. However, we expect differentiation with key secondary endpoints (≥75% reduction in migraine days over weeks 1-12 and weeks 1-4), which we think will be important for commercial success. We maintain our view that there is room for multiple players in the migraine prophylaxis market, and we believe Alder shares remain underappreciated even in a scenario where PROMISE-1 data are positive but undifferentiated. Alder’s current EV (~$550M) reflects treatment of just ~63k patients with eptinezumab in 2027 in our model, or <1% of our estimated 7.1M prevention therapy candidates."" (6/9/2017)
Are investors shorting Alder BioPharmaceuticals?
Alder BioPharmaceuticals saw a increase in short interest during the month of March. As of March 29th, there was short interest totalling 10,860,160 shares, an increase of 17.7% from the March 15th total of 9,228,150 shares. Based on an average daily trading volume, of 2,002,978 shares, the days-to-cover ratio is currently 5.4 days. Currently, 18.6% of the company's stock are short sold.
Who are some of Alder BioPharmaceuticals' key competitors?
Some companies that are related to Alder BioPharmaceuticals include Motif (MTFB), Aimmune Therapeutics (AIMT), Insmed (INSM), Cambrex (CBM), MyoKardia (MYOK), Arena Pharmaceuticals (ARNA), Phibro Animal Health (PAHC), OPKO Health (OPK), Enanta Pharmaceuticals (ENTA), Prestige Brands (PBH), Madrigal Pharmaceuticals (MDGL), Xencor (XNCR), Innoviva (INVA), Akcea Therapeutics (AKCA), Radius Health (RDUS), Prothena (PRTA), Impax Laboratories (IPXL) and Zogenix (ZGNX).
Who are Alder BioPharmaceuticals' key executives?
Alder BioPharmaceuticals' management team includes the folowing people:
- Dr. Randall C. Schatzman Ph.D., Co-Founder, Chief Exec. Officer, Pres and Director (Age 63)
- Dr. John A. Latham, Co-Founder, Chief Scientific Officer & Head of R&D (Age 58)
- Mr. Larry K. Benedict, Principal Accounting Officer and Exec. VP (Age 57)
- Ms. Elisabeth A. Sandoval, Chief Commercial Officer & Exec. VP of Corp. Strategy (Age 56)
- Dr. Timothy M. Whitaker, Consultant (Age 59)
Has Alder BioPharmaceuticals been receiving favorable news coverage?
News coverage about ALDR stock has trended somewhat positive on Thursday, according to Accern Sentiment Analysis. Accern rates the sentiment of press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Alder BioPharmaceuticals earned a coverage optimism score of 0.17 on Accern's scale. They also gave press coverage about the biopharmaceutical company an impact score of 46.37 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days.
Who are Alder BioPharmaceuticals' major shareholders?
Alder BioPharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include
REDMILE GROUP, LLC
(9.99%). Company insiders that own Alder BioPharmaceuticals stock include Jeffrey T L Smith, John A Latham, Mark James Litton, Randall C Schatzman and Stephen M Dow. View Institutional Ownership Trends for Alder BioPharmaceuticals.
How do I buy shares of Alder BioPharmaceuticals?
Shares of ALDR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Alder BioPharmaceuticals' stock price today?
One share of ALDR stock can currently be purchased for approximately $14.30.
How big of a company is Alder BioPharmaceuticals?
Alder BioPharmaceuticals has a market capitalization of $987.14 million and generates $1.62 million in revenue each year. The biopharmaceutical company earns $-288,870,000.00 in net income (profit) each year or ($4.95) on an earnings per share basis. Alder BioPharmaceuticals employs 193 workers across the globe.
How can I contact Alder BioPharmaceuticals?
Alder BioPharmaceuticals' mailing address is 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA, 98011. The biopharmaceutical company can be reached via phone at 425-205-2900 or via email at [email protected]
MarketBeat Community Rating for Alder BioPharmaceuticals (ALDR)
MarketBeat's community ratings are surveys of what our community members think about Alder BioPharmaceuticals and other stocks. Vote "Outperform" if you believe ALDR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALDR will underperform the S&P 500 over the long term. You may vote once every thirty days.
Alder BioPharmaceuticals (NASDAQ:ALDR) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
12 Wall Street analysts have issued ratings and price targets for Alder BioPharmaceuticals in the last 12 months. Their average twelve-month price target is $28.1667, suggesting that the stock has a possible upside of 100.05%. The high price target for ALDR is $51.00 and the low price target for ALDR is $11.00. There are currently 1 sell rating, 1 hold rating and 10 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.75 | 2.77 | 2.77 | 2.75 |
| Ratings Breakdown: | 1 Sell Rating(s)
1 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
1 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
1 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
1 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $28.1667 | $29.3077 | $29.0769 | $30.00 |
| Price Target Upside: | 100.05% upside | 96.70% upside | 62.44% upside | 176.50% upside |
Alder BioPharmaceuticals (NASDAQ:ALDR) Consensus Price Target History
Alder BioPharmaceuticals (NASDAQ:ALDR) Analyst Ratings History
Show:
(Data available from 4/19/2016 forward)
Alder BioPharmaceuticals (NASDAQ:ALDR) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Alder BioPharmaceuticals (NASDAQ ALDR) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 10.60%
Institutional Ownership Percentage: 99.14%
Alder BioPharmaceuticals (NASDAQ ALDR) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 11/13/2017 | Mark James Litton | Insider | Sell | 16,519 | $10.80 | $178,405.20 | 116,451 |  |
| 10/16/2017 | Mark James Litton | Insider | Sell | 16,520 | $12.33 | $203,691.60 | 116,452 | |
| 7/18/2017 | Stephen M Dow | Director | Buy | 25,000 | $10.00 | $250,000.00 | | |
| 6/20/2017 | Jeffrey T L Smith | VP | Sell | 585 | $20.00 | $11,700.00 | 1,416 | |
| 1/18/2017 | Mark James Litton | Insider | Sell | 1,498 | $23.10 | $34,603.80 | 101,430 | |
| 1/9/2017 | Mark James Litton | Insider | Sell | 9,516 | $23.01 | $218,963.16 | | |
| 12/1/2016 | Jeffrey T. L. Smith | VP | Sell | 3,000 | $22.78 | $68,340.00 | | |
| 12/1/2016 | John A. Latham | Insider | Sell | 3,636 | $22.78 | $82,828.08 | | |
| 11/7/2016 | Randall C Schatzman | CEO | Sell | 10,000 | $25.16 | $251,600.00 | 124,768 | |
| 10/17/2016 | Mark James Litton | Insider | Sell | 6,000 | $27.50 | $165,000.00 | 99,567 | |
| 10/3/2016 | Jeffrey T L Smith | VP | Sell | 3,000 | $31.14 | $93,420.00 | 3,000 | |
| 10/3/2016 | John A Latham | Insider | Sell | 10,000 | $31.32 | $313,200.00 | 252,200 | |
| 10/3/2016 | Randall C Schatzman | CEO | Sell | 8,181 | $31.15 | $254,838.15 | 122,949 | |
| 9/1/2016 | Jeffrey T L Smith | VP | Sell | 3,000 | $32.49 | $97,470.00 | 3,000 | |
| 9/1/2016 | Randall C Schatzman | Insider | Sell | 10,000 | $32.48 | $324,800.00 | 124,768 | |
| 8/15/2016 | Jeffrey T L Smith | VP | Sell | 3,000 | $31.17 | $93,510.00 | 3,000 | |
| 8/1/2016 | John A Latham | Insider | Sell | 10,000 | $31.19 | $311,900.00 | 252,200 | |
| 7/27/2016 | John A Latham | Insider | Sell | 10,000 | $30.14 | $301,400.00 | 243,013 | |
| 7/25/2016 | Randall C Schatzman | Insider | Sell | 10,000 | $28.08 | $280,800.00 | 124,768 | |
| 6/13/2016 | Mark James Litton | Insider | Sell | 6,000 | $28.94 | $173,640.00 | 74,567 | |
| 6/3/2016 | Jeffrey T L Smith | VP | Sell | 16,090 | $30.20 | $485,918.00 | 16,090 | |
| 6/1/2016 | John A Latham | Insider | Sell | 10,000 | $30.02 | $300,200.00 | 252,200 | |
| 5/31/2016 | Mark James Litton | Insider | Sell | 25,000 | $30.05 | $751,250.00 | 79,847 | |
| 5/27/2016 | John A Latham | Insider | Sell | 6,401 | $30.05 | $192,350.05 | 248,601 | |
| 5/24/2016 | Randall C Schatzman | CEO | Sell | 10,000 | $28.02 | $280,200.00 | 115,933 | |
| 4/18/2016 | Randall C Schatzman | CEO | Sell | 30,000 | $28.07 | $842,100.00 | 124,409 | |
| 1/4/2016 | Mark James Litton | insider | Sell | 25,000 | $31.40 | $785,000.00 | 73,718 | |
| 1/4/2016 | Randall C. Schatzman | CEO | Sell | 10,000 | $31.47 | $314,700.00 | 111,579 | |
| 12/1/2015 | Jeffrey T. L. Smith | VP | Sell | 4,272 | $37.24 | $159,089.28 | | |
| 12/1/2015 | John A. Latham | insider | Sell | 4,550 | $37.24 | $169,442.00 | 241,726 | |
| 12/1/2015 | Randall C. Schatzman | CEO | Sell | 10,000 | $37.24 | $372,400.00 | 111,579 | |
| 11/30/2015 | Stephen M Dow | Director | Sell | 88 | $37.11 | $3,265.68 | | |
| 11/2/2015 | Jeffrey T. L. Smith | VP | Sell | 3,900 | $33.67 | $131,313.00 | | |
| 11/2/2015 | John A. Latham | insider | Sell | 4,545 | $33.69 | $153,121.05 | 241,265 | |
| 11/2/2015 | Randall C. Schatzman | CEO | Sell | 10,000 | $33.71 | $337,100.00 | 109,921 | |
| 10/1/2015 | Jeffrey T. L. Smith | VP | Sell | 3,900 | $32.25 | $125,775.00 | | |
| 10/1/2015 | John A. Latham | insider | Sell | 4,545 | $32.26 | $146,621.70 | 241,265 | |
| 9/1/2015 | Jeffrey T. L. Smith | VP | Sell | 3,900 | $38.50 | $150,150.00 | | |
| 9/1/2015 | John A. Latham | insider | Sell | 4,545 | $38.52 | $175,073.40 | 209,447 | |
| 8/31/2015 | Stephen M Dow | Director | Sell | 16,218 | $38.75 | $628,447.50 | | |
| 6/12/2015 | Larry Benedict | VP | Sell | 25,454 | $47.46 | $1,208,046.84 | | |
| 6/4/2015 | John A Latham | Insider | Sell | 25,000 | $44.18 | $1,104,500.00 | | |
| 6/1/2015 | Jeffrey T L Smith | VP | Sell | 3,900 | $41.53 | $161,967.00 | | |
| 6/1/2015 | John A Latham | Insider | Sell | 4,545 | $41.53 | $188,753.85 | | |
| 5/22/2015 | Jeffrey T L Smith | VP | Sell | 61,818 | $38.86 | $2,402,247.48 | | |
| 5/21/2015 | Stephen M Dow | Director | Sell | 20,000 | $65.69 | $1,313,800.00 | | |
| 5/20/2015 | Stephen M Dow | Director | Sell | 8,462 | $40.39 | $341,780.18 | | |
| 5/18/2015 | Clay B Siegall | Director | Sell | 38,181 | $37.62 | $1,436,369.22 | | |
| 4/1/2015 | Jeffrey T L Smith | VP | Sell | 3,900 | $27.43 | $106,977.00 | | |
| 4/1/2015 | John A Latham | Insider | Sell | 19,045 | $29.54 | $562,589.30 | | |
| 3/30/2015 | John A Latham | Insider | Sell | 14,500 | $30.20 | $437,900.00 | | |
| 1/27/2015 | Jeffrey T L Smith | VP | Sell | 3,900 | $28.01 | $109,239.00 | | |
| 1/27/2015 | John A Latham | Insider | Sell | 15,045 | $28.33 | $426,224.85 | | |
| 1/27/2015 | Randall C Schatzman | CEO | Sell | 100,000 | $28.42 | $2,842,000.00 | | |
| 1/26/2015 | Jeffrey T L Smith | VP | Sell | 2,700 | $27.89 | $75,303.00 | | |
| 1/26/2015 | Mark James Litton | Insider | Sell | 5,200 | $28.03 | $145,756.00 | | |
| 1/26/2015 | Randall C Schatzman | CEO | Sell | 36,422 | $27.93 | $1,017,266.46 | | |
| 11/24/2014 | Jeffrey T L Smith | VP | Sell | 29,090 | $16.08 | $467,767.20 | | |
| 5/13/2014 | A/S Novo | Insider | Buy | 550,000 | $10.00 | $5,500,000.00 | | |
| 5/13/2014 | Alan Bruce Montgomery | Director | Buy | 3,000 | $10.00 | $30,000.00 | | |
| 5/13/2014 | West 8 Limited Partne Ventures | Major Shareholder | Buy | 250,000 | $10.00 | $2,500,000.00 | | |
(Data available from 1/1/2013 forward)
Alder BioPharmaceuticals (NASDAQ ALDR) News Headlines
| Source: |
|
Alder BioPharmaceuticals (NASDAQ:ALDR) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Alder BioPharmaceuticals (NASDAQ:ALDR) Income Statement, Balance Sheet and Cash Flow Statement
Alder BioPharmaceuticals (NASDAQ ALDR) Stock Chart for Thursday, April, 19, 2018
Loading chart…
